On Jan. 17, the U.S. Food and Drug Administration (FA) approved Voraxaze (glucarpidase) to treat patients with toxic blood levels of methotrexate because of renal failure. Read more.
U.S. Food and Drug Administration (FA) approved Voraxaze (glucarpidase)
Share